Optimi Health Corp. Common Shares (OPTH) - Net Assets
Based on the latest financial reports, Optimi Health Corp. Common Shares (OPTH) has net assets worth $12.42 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.21 Million) and total liabilities ($5.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See OPTH net asset quality score to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.42 Million |
| % of Total Assets | 68.2% |
| Annual Growth Rate | 4.47% |
| 5-Year Change | -68.77% |
| 10-Year Change | N/A |
| Growth Volatility | 129.49 |
Optimi Health Corp. Common Shares - Net Assets Trend (2020–2025)
This chart illustrates how Optimi Health Corp. Common Shares's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see OPTH market cap overview.
Annual Net Assets for Optimi Health Corp. Common Shares (2020–2025)
The table below shows the annual net assets of Optimi Health Corp. Common Shares from 2020 to 2025. Also explore Optimi Health Corp. Common Shares (OPTH) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $6.58 Million | -31.28% |
| 2024-09-30 | $9.58 Million | -27.52% |
| 2023-09-30 | $13.21 Million | -17.54% |
| 2022-09-30 | $16.02 Million | -23.96% |
| 2021-09-30 | $21.07 Million | +298.44% |
| 2020-09-30 | $5.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Optimi Health Corp. Common Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2711103600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $31.74 Million | 482.33% |
| Other Comprehensive Income | $2.12 Million | 32.27% |
| Total Equity | $6.58 Million | 100.00% |
Optimi Health Corp. Common Shares Competitors by Market Cap
The table below lists competitors of Optimi Health Corp. Common Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
eMnet Inc
KQ:123570
|
$24.91 Million |
|
SIAV S.P.A.
F:F4U
|
$24.94 Million |
|
Korean Drug Co. Ltd
KQ:014570
|
$24.94 Million |
|
Xali Gold Corp
V:XGC
|
$24.95 Million |
|
BIONXT SOLUTIONS INC.
F:BXT
|
$24.90 Million |
|
Hunyvers SA
PA:ALHUN
|
$24.90 Million |
|
Aetherium Acquisition Corp
NASDAQ:GMFI
|
$24.90 Million |
|
Lotus Eye Hospital and Institute Limited
NSE:LOTUSEYE
|
$24.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Optimi Health Corp. Common Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,575,712 to 6,579,965, a change of -2,995,747 (-31.3%).
- Net loss of 3,717,287 reduced equity.
- New share issuances of 395,000 increased equity.
- Other comprehensive income increased equity by 95,297.
- Other factors increased equity by 231,243.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.72 Million | -56.49% |
| Share Issuances | $395.00K | +6.0% |
| Other Comprehensive Income | $95.30K | +1.45% |
| Other Changes | $231.24K | +3.51% |
| Total Change | $- | -31.28% |
Book Value vs Market Value Analysis
This analysis compares Optimi Health Corp. Common Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.20x to 2.47x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-09-30 | $2.31 | $5.07 | x |
| 2021-09-30 | $9.05 | $5.07 | x |
| 2022-09-30 | $6.17 | $5.07 | x |
| 2023-09-30 | $4.56 | $5.07 | x |
| 2024-09-30 | $3.21 | $5.07 | x |
| 2025-09-30 | $2.06 | $5.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Optimi Health Corp. Common Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -56.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -870.75%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 2.32x
- Recent ROE (-56.49%) is below the historical average (-39.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -3.20% | 0.00% | 0.00x | 1.17x | $-697.98K |
| 2021 | -28.57% | 0.00% | 0.00x | 1.11x | $-8.13 Million |
| 2022 | -45.89% | -9106.91% | 0.00x | 1.05x | $-8.95 Million |
| 2023 | -39.32% | -2868.54% | 0.01x | 1.25x | $-6.52 Million |
| 2024 | -63.03% | -1548.25% | 0.03x | 1.52x | $-6.99 Million |
| 2025 | -56.49% | -870.75% | 0.03x | 2.32x | $-4.38 Million |
Industry Comparison
This section compares Optimi Health Corp. Common Shares's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $290,420,616
- Average return on equity (ROE) among peers: -51.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Optimi Health Corp. Common Shares (OPTH) | $12.42 Million | -3.20% | 0.47x | $24.91 Million |
| Aurora Cannabis Inc (ACB) | $1.08 Million | -29.24% | 0.07x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $140.89 Million | 0.00% | 0.10x | $138.64 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $-30.58 Million | 0.00% | 0.00x | $241.89 Million |
| Alkermes Plc (ALKS) | $1.11 Billion | -4.33% | 0.82x | $7.72 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $3.58 Billion |
| Amphastar P (AMPH) | $329.25 Million | 3.20% | 0.30x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $5.80 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $20.01 Million | -419.73% | 172.53x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $5.00 Million | -54.00% | 0.38x | $279.44 Million |
About Optimi Health Corp. Common Shares
Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and… Read more